To elucidate the molecular mechanisms underlying the synergistic anti-tumor effect of the alectinib and DNA-demethylating agent combination therapy, we first confirmed the status of DNA methylation and STAT3 phosphorylation in ALCL cells. This evidence concerns the gene STAT3 and neoplasm.